PASCAL Precision Transcatheter Valve Repair System
Edwards Lifesciences, LLC · Decision date Oct 22, 2026
What did the FDA approve?
The FDA database record P220003/S032 lists an approval, dated 2026-10-22, for Edwards Lifesciences, LLC under product code NKM (mitral valve repair devices, cardiovascular specialty). The supplement is categorized as a real-time process submission with the stated reason "Labeling Change - Indications/instructions/shelf life/tradename." The source statement describes the action as approval for extending the device shelf-life to 3-years and revising the shelf-life testing protocol.
The identifier ties the supplement to original PMA P220003 for the PASCAL Precision Transcatheter Valve Repair System; it is a supplement to that PMA, not a new approval of the whole system. The record reports a labeling and protocol change, not clinical outcome data, so it offers no independent proof of safety or effectiveness. Beyond the 3-year target and protocol revision, the record does not disclose the prior shelf-life, the protocol specifics, or which labeling text changed.
FDA approval order statement
Approval for extending the device shelf-life to 3-years and to revise the shelf-life testing protocol
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 22, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P220003/S032
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NKM
- Decision code
- APPR
- Decision date
- Oct 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Mitral valve repair devices.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NKM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220003. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220003 · Original PMA
PASCAL Precision Transcatheter Valve Repair System
P220003/S032 received
Application receipt date recorded by FDA.
P220003/S033 · Related supplement
PASCAL Precision Transcatheter Valve Repair System
P220003/S028 · Related supplement
PASCAL Ace with Capture Clarity Valve Repair System MR Implant System
P220003/S029 · Related supplement
PASCAL Precision Transcatheter Valve Repair System
P220003/S032 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P220003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA approval | Sep 14, 2022 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Sep 9, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Sep 23, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 20, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P220003/S032
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records